We are monitoring the impact of COVID-19 on APAC Pharmacovigilance Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 7550
Share on
Share on

Asia Pacific Pharmacovigilance Market Research Report - Segmented By Clinical Trial Phase, By Service Provider, By Method & By Country(India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) - Industry Analysis, Size, Share, Growth, Trends, And Forecasts(2019-2024)

Pulished: February, 2020
ID: 7550
Pages: 145

As per the research report, the Asia Pacific Pharmacovigilance Market was worth USD 0.930 Billion in 2019 and estimated to be growing at a CAGR of 14.86%, to reach USD 1.86 billion by 2024 during the forecast period.

Pharmacovigilance is the science and activities related to the detection, assessment, understanding and prevention of adverse effect and another drug-related problem. The goals of pharmacovigilance are to provide patient safety by providing a system to collect assess and distribute drug safety data. It also involves monitoring approved drugs and investigational medicine product (IMPs).

The APAC region has the fastest growth rate of the pharmacovigilance market. The number of adverse drug reaction is increasing in the area; thus, there is a rise in the demand for pharmacovigilance. The biopharmaceutical sector in the region is developing, and there is a lot of research going in the region on drugs, thus increasing the demand of pharmacovigilance market. The number of clinical trials in the region is rising, which are working on developing innovative medicines and vaccines, which is solely propelling market growth. The countries like India, China, Japan and Australia have the modern infrastructure for pharmacovigilance. The Indian Pharmacopoeia Commission started a training course for the WHO members in the region. 

Lack of standardization is a major factor restraining the demand of the market. The number of the skilled workforce for pharmacovigilance is less due to less training programs which are slowly hampering the demand of the market in the Asia Pacific. Lack of awareness in undeveloped countries is hindering the growth rate of the market. Stringent rules and regulations by the government are also impeding the demand of the market. 

This research report segmented and sub-segmented into the following categories:

  • By Clinical Trial Phase: Pre-clinical, Phase I, Phase II, Phase III and Phase IV
  • By Service Provider: In-house and Contract Outsourcing
  • By Method: Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining             
  • By Country: India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC.

Regional Analysis

The Indian pharmacovigilance market is growing at a brisk pace. The Indian government launched the PvPI (Pharmacovigilance program of India) with the NCC (National Coordination Centre) which monitors the adverse drug reaction in India. Rising geriatric population is also a factor for the growth of the market. 

China pharmacovigilance market has the largest share in the Asia Pacific market. The Chinese pharmacovigilance market is one of the leading markets in the world. The government has launched the CADRMS (china adverse drugs reaction monitoring system) for monitoring the ADRs in the country. 

Australia and the rest of APAC are to have significant growth rate in the coming years. Escalating expenditure on healthcare is to lavish the growth rate of the market in the coming years. 

The Top companies leading in the APAC Pharmacovigilance Market profiled in the report are Boehringer Ingelheim, Accenture, Bristol-Myers Squibb, Covance, ICON, PAREXEL, Quintiles, United BioSource, Synowlwedge and Cognizant Technology Solutions Corporation.

1. Introduction           

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods    

                1.4 General Study Assumptions                

2. Research Methodology                     

                2.1 Introduction         

                2.2 Research Phases

          2.2.1 Secondary Research           

          2.2.2 Primary Research 

          2.2.3 Econometric Modelling      

          2.2.4 Expert Validation  

                2.3 Analysis Design   

                2.4 Study Timeline    

3. Overview                 

                3.1 Executive Summary                

                3.2 Key Inferences   

                3.3 Epidemology        

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)              

                4.1 Market Drivers    

                4.2 Market Restraints                    

                4.3 Key Challenges   

                4.4 Current Opportunities in the Market        

5. Market Segmentation  

                5.1 Clinical trial phase                    

          5.1.1 Introduction           

          5.1.2 Pre-clinical               

          5.1.3 Phase I      

          5.1.4 Phase II    

          5.1.5 Phase III   

          5.1.6 Phase IV   

          5.1.7  Y-o-Y Growth Analysis, By Clinical trial phase           

          5.1.8  Market Attractiveness Analysis, By Clinical trial phase         

          5.1.9  Market Share Analysis, By Clinical trial phase          

                5.2 Service provider 

          5.2.1 Introduction           

          5.2.2 In-house  

          5.2.3 Contract outsourcing          

          5.2.4 Y-o-Y Growth Analysis, By Service provider              

          5.2.5 Market Attractiveness Analysis, By Service provider            

          5.2.6 Market Share Analysis, By Service provider              

                5.3 Method 

          5.3.1 Spontaneous Reporting    

          5.3.2 Intensified ADR Reporting

          5.3.3 Targeted Spontaneous Reporting 

          5.3.4 Cohort Event Monitoring  

          5.3.5 EHR Mining             

          5.3.5 Y-o-Y Growth Analysis, By Method               

          5.3.6 Market Attractiveness Analysis, By Method             

          5.3.7 Market Share Analysis, By Method              

6. Geographical Analysis  

                6.1 Introduction         

          6.1.1 Regional Trends    

          6.1.2 Impact Analysis     

          6.1.3 Y-o-Y Growth Analysis        

    6.1.3.1 By Geographical Area

    6.1.3.2 By Clinical trial phase

    6.1.3.3 By Service provider

    6.1.3.4 By Method

          6.1.4  Market Attractiveness Analysis     

    6.1.4.1 By Geographical Area

    6.1.4.2 By Clinical trial phase

    6.1.4.3 By Service provider

    6.1.4.4 By Method

          6.1.5  Market Share Analysis      

    6.1.5.1 By Geographical Area

    6.1.5.2 By Clinical trial phase

    6.1.5.3 By Service provider

    6.1.5.4 By Method

                6.2 China       

                6.3 India        

                6.4 Japan      

                6.5 South Korea         

                6.6 Australia

7. Strategic Analysis                 

                7.1 PESTLE analysis   

          7.1.1 Political     

          7.1.2 Economic 

          7.1.3 Social         

          7.1.4 Technological         

          7.1.5 Legal          

          7.1.6 Environmental       

                7.2 Porter’s Five analysis        

          7.2.1 Bargaining Power of Suppliers        

          7.2.2 Bargaining Power of Consumers    

          7.2.3 Threat of New Entrants     

          7.2.4 Threat of Substitute Products and Services              

          7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                  

                8.1 Boehringer Ingelheim      

          8.1.1 Overview 

          8.1.2 Product Analysis   

          8.1.3 Financial analysis  

          8.1.4 Recent Developments       

          8.1.5 SWOT analysis       

          8.1.6 Analyst View          

                8.2 Accenture                   

                8.3 Bristol-Myers Squibb        

                8.4 Covance 

                8.5 ICON       

                8.6 PAREXEL

                8.7 Quintiles

                8.8  United BioSource                    

                8.9 Synowlwedge     

                8.10 Cognizant Technology Solutions Corporation      

9. Competitive Landscape                     

                9.1 Market share analysis      

                9.2 Merger and Acquisition Analysis 

                9.3 Agreements, collaborations and Joint Ventures   

                9.4 New Product Launches   

10. Market Outlook and Investment Opportunities                   

Appendix                     

                a) List of Tables                

                b) List of Figures        

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia Pacific Pharmacovigilance  Market By Clinical trial phase, From 2019-2024 ( USD Billion )
  2. Asia Pacific Pre-clinical Market By Region, From 2019-2024 ( USD Billion )
  3. Asia Pacific Phase I Market By Region, From 2019-2024 ( USD Billion )
  4. Asia Pacific Phase II Market By Region, From 2019-2024 ( USD Billion )
  5. Asia Pacific Phase III Market By Region, From 2019-2024 ( USD Billion )
  6. Asia Pacific Phase IV Market By Region, From 2019-2024 ( USD Billion )
  7. Asia Pacific Pharmacovigilance  Market By Service provider, From 2019-2024 ( USD Billion )
  8. Asia Pacific In house Market By Region, From 2019-2024 ( USD Billion )
  9. Asia Pacific Contract outsourcing Market By Region, From 2019-2024 ( USD Billion )
  10. Japan Pharmacovigilance  Market By Clinical trial phase, From 2019-2024 ( USD Billion )
  11. Japan Pharmacovigilance  Market By Service provider, From 2019-2024 ( USD Billion )
  12. China Pharmacovigilance  Market By Clinical trial phase, From 2019-2024 ( USD Billion )
  13. China Pharmacovigilance  Market By Service provider, From 2019-2024 ( USD Billion )
  14. India Pharmacovigilance  Market By Clinical trial phase, From 2019-2024 ( USD Billion )
  15. India Pharmacovigilance  Market By Service provider, From 2019-2024 ( USD Billion )
  16. Australia Pharmacovigilance  Market By Clinical trial phase, From 2019-2024 ( USD Billion )
  17. Australia Pharmacovigilance  Market By Service provider, From 2019-2024 ( USD Billion )
  18. South Korea Pharmacovigilance  Market By Clinical trial phase, From 2019-2024 ( USD Billion )
  19. South Korea Pharmacovigilance  Market By Service provider, From 2019-2024 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample